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Abstract Recent studies using HeLa in vitro splicing extracts have shown that changes in the relative concentrations of constitutive protein splicing 
factors can affect the choice between competing 5’ splice sites in alternatively spliced mammalian pre-mRNAs. Here we report that treatment of a 
HeLa splicing extract with human protein phosphatase 1 strongly inhibits formation of mRNA spliced to the distal 5’ splice site while stimulating 
relative use of the proximal 5’ splice site. This effect is not observed if spliceosomes assemble prior to protein phosphatase 1 treatment. These data 
show that alternative splicing in HeLa extracts can be mediated by changes in protein modification as well as by changes in the relative concentration 
of splicing factors. Changes in protein phosphorylation may thus provide a rapid mechanism for cells to respond to stimuli that require an alteration 
in alternative splicing patterns. 
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1. Introduction 
The removal of introns from mRNA precursor transcripts 
(pre-mRNA) is an essential step during the expression of most 
genes in higher eukaryotes [1,2]. Intron removal takes place in 
the nucleus and is performed by a dedicated splicing machinery, 
termed the spliceosome, whose principal subunits are the Ul, 
U2 and [U4/U6.U5] small nuclear ribonucleoprotein particles 
(snRNPs). Each snRNP comprises one or more small nuclear 
RNA and a set of proteins [3]. The snRNPs, together with 
additional non-snRNP protein splicing factors [4], assemble on 
pre-mRNAs in a stepwise pathway to form active spliceosomes. 
Detailed studies on the mechanism of splicing have been facil- 
itated by the development of in vitro systems from both HeLa 
cells and budding yeast that accurately remove introns from 
exogenously added pre-mRNAs [2,5,6]. 
In addition to being an essential step for producing func- 
tional mRNA, splicing can be exploited as a versatile post- 
transcriptional regulatory mechanism. For example, by regu- 
lating the choice of alternative splice sites in a pre-mRNA, 
distinct mRNAs, and hence distinct protein products, can be 
generated from the same primary transcript. There are now 
many examples where such regulated splicing events are known 
to control biological processes [7,8]. Previous in vitro studies 
have shown that several members of the SR family of non- 
snRNP protein splicing factors can influence 5’ splice site 
choice in mammalian pre-mRNAs [9-161. Specifically, in pre- 
mRNAs with alternative, competing 5’ splice sites, high concen- 
trations of SR proteins favour the selection of proximal over 
distal 5’ splice sites. Conversely, high concentrations of the 
heterogeneous nuclear ribonucleoprotein (hnRNP) Al, favour 
use of distal over proximal 5’ splice sites [ 121. Alternative splic- 
ing, at least in some cases, may thus be controlled by the 
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balance between the relative concentrations of factors such as 
SR proteins and hnRNPA1 in the nucleus. 
The SR proteins represent a family of nuclear phosphopro- 
teins that share a common motif of repeating arginine-serine 
dipeptides and are highly conserved between mammals and 
drosophila [4,17,18]. They can be conveniently copurified by a 
two step salt precipitation method [19]. Interestingly, as well as 
their role in alternative splicing, SR proteins also have an essen- 
tial function(s) in constitutive splicing. This has been demon- 
strated by the observation that HeLa SlOO extracts, which are 
inactive for splicing, can be activated to splice pre-mRNA by 
adding exogenous SR proteins. There is also some functional 
redundancy between members of the SR protein family since 
splicing in HeLa SlOO extracts can be activated by adding 
different SR proteins individually. There is good evidence that 
SR proteins are required at a very early stage of spliceosome 
assembly [I l-161. However, the mechanism by which they influ- 
ence alternative splicing, or splicesome assembly, is still not 
understood. 
Recently, evidence has emerged from studies using HeLa in 
vitro splicing extracts that reversible Ser/Thr-specific protein 
phosphorylation can influence both spliceosome assembly and 
the catalytic steps of the splicing reaction [20-221. For example, 
addition of the specific protein phosphatase inhibitors okadaic 
acid, tautomycin or microcystin-LR to HeLa splicing extracts 
inhibits splicing but not spliceosome assembly [20,21]. A similar 
effect is obtained when a thiophosphorylated erivative of the 
Ul snRNP-specific 70 kDa protein is added to the extract [22]. 
In contrast, treatment of the HeLa extract with purified protein 
phosphatase 1 (PPl) potently inhibits spliceosome assembly 
(Mermound et al., EMBO J., in press). Collectively, these data 
indicate that protein phosphorylation may have a role in regu- 
lating constitutive pre-mRNA splicing events, both positively 
and negatively. In this study we report evidence that reversible 
protein phosphorylation may also have a role in regulating 
alternative splicing events. We demonstrate that for three sepa- 
rate pre-mRNAs which have alternative, competing 5’ splice 
sites, treatment of HeLa splicing extracts with purified PPl in 
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each case enhances relative utilisation of the proximal over the 
distal 5’ splice site. 
2. Experimental 
2. I. Splicing assays 
HeLa nuclear splicing extracts were prepared as described by Dig- 
nam et al. [23] using the modifications described by Barabino et al. [24]. 
Pre-mRNA was prepared by in vitro transcription and used in splicing 
assays as described by Lamond et al. [25]. All splicing assays were 
carried out for 120 min at 30°C in a total reaction volume of 20@. RNA 
products of the splicing reaction were analysed by electrophoresis on 
a 7% denaturing polyacrylamidell M urea gel. Splicing complexes were 
analysed on non-denaturing agarose-acrylamide composite gels, as de- 
scribed in Lamond et al. [26]. 
2.2. Analysis of alternatively spliced RNAs 
RNAs spliced to the cryptic 5’ splice site were eluted from the gel in 
300 ~1 of 0.2 M sodium acetate, pH 7, 0.1 mM EDTA in the presence 
of 5 pg tRNA carrier. After elution overnight at room temperature, the 
RNA was extracted once with an equal volume of phenol/chloroform 
(l:l, v/v), and precipitated from the supematant by addition of 2.5 
volumes ethanol. The eluted RNAs were copied into cDNA using AMV 
Reverse Transcriptase as described in Sambrook et al. (271, amplified 
by the PCR method [28] and sequenced irectly without subcloning of 
the amplified product [29]. 
2.3. Isolation of SR proteins 
SR proteins were isolated from HeLa cells according to the method 
of Zahler et al. [19] and analysed by Coomassie staining after PAGE 
separation. As a functional control, isolated SR proteins were shown 
to stimulate splicing in a HeLa SIOO extract (data not shown). The SR 
proteins were added to HeLa nuclear extracts prior to addition of 
pre-mRNA at the start of the splicing assays. 
2.4. Preparation of PPI 
Cloned human PPly [30] was expressed in E. coli and purified to 
homogeneity as described by Alessi et al. [31]. One unit of PPl activity 
is defined as the amount of activity that catalyses the dephosphoryla- 
tion of lnmole of glycogen phosphorylase in 1 minute. PPly was stored 
at a concentration of 30-60 units/@ in 50% glycerol, 50 mM Tris-HC1 
pH 7.5,O. 1 mM EGTA, 0.1% mercaptoethanol. Prior to use the enzyme 
was diluted into 20 mM HEPES pH 7.9, 20% glycerol, 0.1 M KCI, 0.2 
mM EDTA. PPly was added to the HeLa extract at a final concentra- 
tion of 0.1 units/@ prior to addition of the pre-mRNA at the start of 
the assay. 
2.5. Construction of plasmidr encoding pre-mRNAs with alternative 
5’ splice sites 
Alternatively spliced pre-mRNAs BCl and BC2 were prepared by in 
vitro transcription of PvuII cut plasmids pBSBC1 and pBSBC2 respec- 
tively, using phage T3 RNA polymerase. The pBSBCl and pBSBC2 
constructs were made by modifying the plasmid pBSALA [25]. Briefly, 
pBSAL4 was cut at the unique Sty1 site in the intron sequence and 
double stranded DNA oligonucleotides BCI (5’CATGTAGCTTC 
GAAACAGGTAAGTCTCGAC-3’) or BC2 (5’-CATGTAGCTTG- 
CTCTAAGGTAAATATCGAC-3’) inserted. Recombinants with cor- 
rectly oriented inserts were isolated and their structures confirmed by 
DNA sequencing using standard methods. 
3. Results 
We have observed that addition of exogenous SR proteins 
to HeLa nuclear extract can activate a previously silent cryptic 
5’ splice site within an intron derived from the major late tran- 
script of adenovirus (adeno pre-mRNA) (Fig. 1A). This cryptic 
5’ splice site was mapped and the alternatively spliced mRNA 
product sequenced (data not shown). The cryptic site (i.e. 
5’ splice site proximal to the 3’ exon) has a 5/8 match to the 
consensus mammalian 5’ splice site sequence [1,2], while the 
constitutively used 5’ splice site (i.e. 5’ splice site distal to the 
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Fig. 1. SR proteins activate a cryptic 5’ splice site in adeno pre-mRNA. 
(A) A pre-mRNA substrate derived from the major late transcription 
unit of adenovirus [22] was incubated in HeLa nuclear splicing extract 
either without exogenous SR proteins (lane 2) or in the presence of I .5 
pg, 3 pg or 5 pg exogenously added SR proteins (lanes 3-5). The 
identity of the RNA intermediates and products of the splicing reaction 
are cartooned at the right hand side of the figure with all species derived 
from use of the proximal (i.e. cryptic) 5’ splice site marked by an 
asterisk. Lane 1 shows unsphced adeno me-mRNA and the lane 
marked M shows DNA size markers derived from an MspI digest of 
oBR322 DNA end-labeled using Klenow nolvmerase and lcc-32PldCTP. 
iB) The alternative 5’ splice sit& in adeno ire-mRNA a;e illustrated 
along with the respective sequences at the competing proximal and 
distal 5’ splice junctions. 
3’ exon) has a 7/S match to the consensus (Fig. 1B). The effect 
of the SR proteins is complex, since addition of lower levels of 
SR proteins stimulates use of the distal 5’ splice site, while at 
higher levels they activate the proximal (i.e. cryptic) 5’ splice site 
and reduce utilisation of the distal site (Fig. lA, lanes 2-5 and 
other data not shown). At the highest concentration used, addi- 
tion of the exogenous SR proteins results in inactivation of the 
distal 5’ splice site while the proximal 5’ splice site remains 
active (Fig. lA, lane 5). These results are consistent with previ- 
ous reports showing the effect of SR proteins on alternative 
splicing, although in all cases the mechanism involved is un- 
known. 
We have recently observed that constitutive splicing and 
spliceosome assembly is inhibited when HeLa nuclear extracts 
are treated with human SerfThr-specific protein phosphatase 
ly (PPly) (Mermoud et al., EMBO J., in press). Remarkably, 
when this experiment is repeated in an extract where addition 
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Fig. 2. PPly differentially inhibits competing 5’ splice sites. The adeno 
pre-mRNA was incubated in HeLa nuclear splicing extract supple- 
mented with 3.ug of exogenous SR proteins either in the absence (lane 
1), or presence (lane 2), of 0.1 units/@ (final concentration) of purified, 
E. coli expressed human PPly. The identity of the RNA intermediates 
and products of the splicing reaction are cartooned at the left hand side 
of the figure with all species derived from use of the proximal 5’ splice 
site marked by an asterisk. The mRNA products formed using the 
proximal (a) and distal (b) 5’ splice sites are marked by arrowheads at 
the right hand side of the figure. The lane marked M shows DNA size 
markers derived from an MspI digest of pBR322 DNA end-labeled 
using Klenow polymerase and [a-‘*P]dCTP. 
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of SR proteins has activated cryptic splice site utilisation in 
adeno pre-mRNA, PPly inhibits splicing from the distal, but 
not from the proximal, 5’ splice site (Fig. 2, compare levels of 
mRNA spliced to the proximal 5’ splice site (arrowhead a) and 
to the distal 5’ splice site (arrowhead b) in lanes 1 and 2). This 
indicates that utilisation of the two alternative 5’ splice sites in 
the adeno pre-mRNA is differentially sensitive to protein 
dephosphorylation. Since the PPly used is a human enzyme 
that was expressed in E. cofi from the cloned PPly gene and 
purified to homogeneity [30,31], the differential inhibition of 
proximal and distal 5’ splice sites cannot be due to exogenous 
mammalian splicing factors contaminating the PPly prepara- 
tion. Control experiments confirm that it is also not caused by 
E. coli proteins (data not shown). We conclude, therefore, that 
PPl treatment is responsible for changing the relative utilisa- 
tion of the competing 5’ splice sites. 
We next addressed whether PPly had a similar effect on 
other pre-mRNAs that utilise alternative 5’ splice sites. There- 
fore, two constructs were made in which either the consensus 
5’ splice site sequence (BCl), or the SV40 t antigen 5’ splice site 
sequence (BC2), was inserted into an intron derived from the 
rabbitSglobin gene (Fig. 3A). In each case, the pre-mRNA has 
a distal 5’ splice site corresponding to the normal /I-globin 
sequence and a proximal 5’ splice site corresponding to the 
inserted sequence. As in the previous experiments, use of the 
proximal 5’ splice site in both constructs is increased by addi- 
tion of SR proteins to the splicing assay (Fig. 3B). The identities 
of the alternatively spliced products were confirmed in each 
case by sequence analysis (data not shown). Adding low levels 
of exogenous SR proteins again increases use of both proximal 
and distal splice sites, while addition of higher levels of SR 
proteins increases the fraction of pre-mRNA spliced to the 
proximal 5’ splice site (Fig. 3B). Treatment of the HeLa splicing 
extract with PPl y resulted in preferential inhibition of the distal 
C 
Fig. 3. PPly selectively inhibits use of distal 5’ splice sites in separate alternatively spliced pre-mRNAs. (A) Cartoon illustrates the structures of the 
alternatively spliced pre-mRNA constructs BCl and BC2. In both constructs the distal 5’ splice site corresponds to the natural 5’ splice site of the 
large intron of rabbit p-globin, while the proximal 5’ splice sites correspond to either the 5’ splice site consensus equence (BCl), or the SV40 t antigen 
5’ splice site. (B) Splicing assays were carried out using both BCl (lanes l-5) or BC2 (lanes 610) pre-mRNAs, either in the absence of exogenous 
SR proteins (lanes 2 and 7), or in the presence of 1.5 pg (lanes 3 and 8) 3 pg (lanes 4 and 9) or 5 pg (lanes 5 and 10) exogenous SR proteins. Lanes 
1 and 6 show markers corresponding to the unspliced BCl and BC2 pre-mRNAs, respectively. The lariat intermediates and products migrate more 
slowly than the unspliced pre-mRNA as previously described for the parent globin construct [25]. (C) Splicing assays using either BCl (lanes 1 and 
2), or BC2 (lanes 3 and 4), pm-mRNAs were carried out in HeLa extracts supplemented with 3 pg SR proteins either in the absence (lanes 1 and 
3), or presence (lanes 2 and 4), of 0.1 units/@ (final concentration) of purified, E. coli expressed human PPly. The cartoons at the left hand side of 
gels B and C show unspliced pre-mRNA and mRNA formed using either the proximal 5’ splice site (asterisk) or distal 5’ splice site. Lanes M 
correspond to DNA size markers derived from an MspI digest of pBR322 DNA end-labeled using Klenow polymerase and [a-“P]dCTP. 
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5’ splice site for both constructs (Fig. 3C). Although the effect 
is less dramatic than seen with adeno pre-mRNA, the ratio of 
mRNA product spliced to the proximal, rather than distal, 5’ 
splice site of both constructs is increased in extracts incubated 
with PPly. PPl y thus has a qualitatively similar effect on alter- 
native splice site selection for three separate proximal 5’ splice 
site sequences and in the context of two distinct intron back- 
grounds. 
Splicing of pre-mRNA is a multi-step process involving two, 
distinct catalytic steps preceded by a complex pathway of 
spliceosome assembly [1,2,5,6]. The requirement for assembly 
of spliceosomes on pre-mRNA produces a lag phase of 15-20 
min before spliced products are detected uring in vitro splicing 
assays. Therefore, we next compared the effect of treating the 
HeLa splicing extract with PPly either prior to spliceosome 
assembly (i.e. adding PPly and pre-mRNA simultaneously to 
the extract), or after assembly, but prior to catalysis (i.e. adding 
PPly 15 min after adding pre-mRNA to the extract). The time 
of addition of PPly significantly affected its ability to influence 
5’ splice site selection (Fig. 4A). Thus, the same amount of 
enzyme that caused preferential utilisation of the proximal 
5’ splice site when added at the start of the reaction, (Fig. 4A, 
lane 6) had little or no effect on 5’ splice site choice when added 
after 15 min (Fig. 4A, compare lane 9 with lanes 3 and 6). 
Parallel native gel analysis confirmed that when PPly was 
added to the splicing reaction after 15 min spliceosomes had 
already assembled (Fig. 4B, lane 8). Interestingly, treatment of 
the HeLa extract with PPl also resulted in much of the splicing 
complexes accumulating at the top of the native gel, suggesting 
that PPl treatment may lead to some form of higher order 
complexes being produced (Fig. 4B, lanes 5,6,8 and 9). 
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These data demonstrate that the PPly does not simply have 
a non-specific inhibitory effect on the catalysis of splicing at 
certain splice sites. The data favour a model in which PPly 
either prevents spliceosome assembly at distal 5’ splice sites, or 
causes the complexes assembled at distal 5’ splice sites to re- 
main inactive. The resistance to PPly treatment after spliceo- 
some assembly has taken place could result either from the 
target proteins whose activity is affected only being required at 
early stages of spliceosome assembly, or, alternatively, from 
spliceosome assembly preventing access of PPly to the key 
targets. 
4. Discussion 
We have shown using a HeLa in vitro splicing extract that 
a protein phosphorylation mechanism can influence the relative 
utilisation of competing 5’ splice sites in alternatively spliced 
mammalian pre-mRNAs. Treatment of the HeLa extract with 
PPly increases the proportion of RNA that is spliced to the 5’ 
splice site proximal to the 3’ exon. The mechanism whereby 
PPly differentially inhibits use of distal 5’ splice sites remains 
to be determined. The mechanism of action of SR proteins, 
which also result in a preferential use of proximal 5’ splice sites, 
is similarly unknown [4,9-191. Interestingly, SR proteins are 
highly phosphorylated in vivo and are required for early steps 
during spliceosome assembly [g-19]. The alternative splicing 
activity of SR proteins could thus be influenced by PPly. The 
level of SR proteins used in these experiments is likely higher 
than the concentration in vivo. This may reflect differences in 
the efficiency of the splicing reaction in the in vitro extract 
compared with the splicing reaction that takes place on nascent 
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Fig. 4. Time of PPly addition influences 5’ splice site selection. (A and B) Splicing assays, using adeno pre-mRNA, were carried out in HeLa nuclear 
splicing extract supplemented with 3 pg exogenous SR proteins, either in the absence (lanes l-3), or in the presence (lanes 49), of 0.1 units&l (final 
concentration) of human PPly. Analysis of RNA products is shown in panel A and analysis of splicing complexes formed in the same reactions i  
panel B. In the reactions hown in lanes 46, PPly was added to the splicing reaction prior to the pre-mRNA at the start of the assay, while in the 
reactions hown in lanes 7-9, the enzyme was dded 15 min after the start of the assay. RNAs from the separate reactions wereanalysed at to (lanes 
1,4 and 7), after 15 min incubation at 30°C (lanes 2,5 and 8) and after 90 min incubation at 30°C (lanes 3,6 and 9). The identity of the RNA 
intermediates and products of the splicing reaction in panel A are cartooned at the left hand side of the figure with all species derived from use of 
the proximal 5’ splice site marked by an asterisk. The mRNA products formed using the proximal (a) and distal (b) 5’ splice sites are marked by 
arrowheads at the right hand side of the figure. The lane marked M shows DNA size markers derived from an MspI digest of pBR322 DNA 
end-labeled using Klenow polymerase and [a-“P]dCTP. (B) In the native gel B and C indicate spliceosome complexes, A indicates pre-spliceosomes 
and H unspecific omplexes. 
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transcripts in vivo. However, if their activity is indeed regulated 
through their phosphorylation state, the concentration of ac- 
tive SR proteins in the splicing extract may in fact be within the 
physiological range. 
Recent studies have shown that the heterogeneous nuclear 
ribonucleoprotein (hnRNP)Al acts antagonistically to SR pro- 
teins, i.e. increasing concentration of hnRNP Al promotes 
selection of distal over proximal 5’ splice sites [12]. Since 
hnRNP Al is also a phosphoprotein in vivo [32], downregula- 
tion of hnRNP Al by PPly treatment may also contribute to 
the observed effects on alternative splicing. Another 
phosphoprotein that plays an important role during early steps 
of spliceosome assembly is the 70 kDa antigen which is a spe- 
cific component of Ul small nuclear ribonucleoprotein (Ul 
snRNP) [3]. Thiophosphorylation of Ul 70 kDa has been 
shown to inhibit splicing catalysis, but not spliceosome assem- 
bly, for a constitutively spliced mammalian pre-mRNA [22]. 
Although Ul snRNP has so far not been implicated as an 
alternative splicing factor, it is known to bind to 5’ splice sites 
and is essential for splicing [1,2,5,6]. It is possible, therefore, 
that the phosphorylation state of the 70 kDa protein could 
contribute to the differential selection of proximal and distal 
5’ splice sites. Whether SR proteins, hnRNP Al, Ul 70 kDa or 
other splicing factors are responsible for the effect of PPly on 
alternative splicing remains to be addressed in future studies. 
The observation that treatment of HeLa splicing extracts 
with human PPly selectively inhibits formation of mRNA 
spliced to a distal 5’ splice site could result either from PPly 
acting directly on one or more splicing factors, or from an 
indirect effect of PPly (e.g. modulation of a kinase in the HeLa 
extract), which in turn affects the activity of splicing factors. 
Since the HeLa splicing system corresponds to a crude nuclear 
extract that contains both endogenous kinase and phosphatase 
activities, it is possible that a phosphorylation cascade is taking 
place and that PPl treatment affects this cascade rather than 
acting itself on a splicing factor. It is also possible that the 
effects we observe in vitro using purified PPl could be mediated 
in vivo by a different protein phosphatase with overlapping 
substrate specificity. However, despite the crude nature of the 
HeLa extract, the inhibitory effects of PPl and of phosphatase 
inhibitors on splicing are clearly very specific. 
It is known that changes in gene expression in vivo can be 
induced by signal transduction pathways that influence phos- 
phorylation activity in the nucleus. The data presented here 
raise the possibility that this may be achieved, in certain cases, 
via changes in alternative splicing patterns. A change in the 
activity of one or more splicing factors promoted by a protein 
phosphorylation mechanism, rather than a change in the con- 
centration of splicing factors within cells, could provide a rapid 
and flexible way of regulating gene expression at the post- 
transcriptional evel. Future studies will, therefore, be directed 
towards analysing the physiological significance of protein 
phosphorylation for alternative splicing in vivo. 
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